- AdventHealth
The AdventHealth Heart, Lung and Vascular Institute recently designed a new program, called the Comprehensive Atrial Fibrillation to help treat patients with long-standing Atrial Fibrillation (AFib) by combining a multidisciplinary approach and offering a minimally invasive procedure to improve, and potentially cure, the most common type of heart arrhythmia.
According to the National Library of Medicine, the success rate of this type of surgery is 60-80% globally.
HOW IT WORKS:
This FDA-approved hybrid approach involves two procedures – a catheter-based ablation and FDA-approved minimally-invasive epicardial ablation. This surgical treatment involves using thoracoscopic cameras to make small incisions in order to perform a surgical ablation, which historically would involve an open-heart surgery procedure.
“Instead of opening your chest and going inside the heart to fix AFib, we can make the same type of lesions on the outside of the heart using cameras to guide us, without stopping it, and only make a 2-centimeter incision at the base of your chest,” said Dr. David Spurlock, a cardiothoracic surgeon at AdventHealth Orlando.
The program works by electrophysiologists (EP) referring patients to Spurlock for the first procedure on the heart. Then, four to eight weeks later, the patient goes back to the electrophysiologist for the second minimally invasive procedure called an endocardial ablation.
“In this procedure, we ablate the inside of the heart by simply accessing veins in the legs, and the benefit of this hybrid approach with the surgeon ablating the outside of the heart and the electrophysiologist ablating the inside of the heart is that it in a group of patients with longstanding atrial fibrillation it increases the chances of being able to maintain normal rhythm long term” said Dr. Mahmoud Altawil, an electrophysiologist at AdventHealth Orlando.
In addition, because Dr. Spurlock clips the left atrial appendage during his portion of the procedure many of these patients will be able to come off blood thinners at some point which is another added benefit.
GO DEEPER:
To learn more about the new Comprehensive AFib program, click here.
For cardiologists and EPs at AdventHealth, this new program is currently available in Epic as “New Patient Consult with AFib.” All other physicians can contact AdventHealth Cardiovascular Surgery Orlando at Call407-425-1566 for more information or to discuss potential cases.
Recent News
Kidney-tumor patients have an innovative new treatment option, first performed recently by a surgical team at AdventHealth Celebration.
Test Apple Podcast
As the Official Healthcare Provider of the 2024 NASCAR Chicago Street Race, we’re thrilled to support such a memorable experience with this amazing community.
The innovative new treatment targets and destroys tumors using sound beams, noninvasively and without the need for needles and incisions.
A summary of the article goes here. A summary of the article goes here. A summary of the article goes here. A summary of the article goes here.
The innovative new treatment targets and destroys tumors using sound beams, noninvasively and without the need for needles and incisions.
Dr. Corbin on the gut microbiome research study
A genetic test, originally conducted to help better understand her daughter's diagnosis, revealed Samantha Arceneaux carries a genetic variant that virtually guarantees she will develop an aggressive...
Under the leadership of investigator Guru Sonpavde, MD, AdventHealth’s Clinical Research Unit (CRU), a collaborative between the AdventHealth Cancer Institute and AdventHealth Research Institute, is...
The AdventHealth Research Institute recently launched two new clinical studies to better understand and address the needs of healthcare employees who work night shifts.
In January 2024, AdventHealth Celebration neurotologist Michael Seidman, MD, FACS, became the first in Florida and the Southeast to complete a robotics-assisted cochlear implant procedure using the...
The CheckMate 901 Phase III clinical trial results, recently published in the New England Journal of Medicine, found that combining the programmed death 1 (PD1) inhibitor immunotherapy nivolumab with...